A Study of AK112 for Advanced Solid Tumors

NCT ID: NCT04597541

Last Updated: 2025-03-10

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 59 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-10-21
• Study Completion Date: 2024-07-15

Brief Summary

This study is to characterize the safety, tolerability, pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD) and anti-tumor activity of AK112, a PD-1/VEGF bispecific antibody, as a single agent in adult subjects with advanced solid tumor malignancies. This trial is a two parts, phase I/II study. All patients are advanced solid tumor, Eastern Cooperative Oncology Group (ECOG) performance status 0-1. Part one is dose escalation phase,part two is dose expansion phase. The primary end point is safety. Secondary end points are objective response rate,progression-free survival and overall survival per RECIST1.1.

Conditions

Solid Tumor, Adult

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

1

AK112

Group Type: EXPERIMENTAL

AK112

Intervention Type: DRUG

AK112 is a PD1/VEGF bispecific antibody;AK112 is given by intravenous infusion.

Interventions

AK112

AK112 is a PD1/VEGF bispecific antibody;AK112 is given by intravenous infusion.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Aged 18 to 75 years old (at the time consent is obtained);
• Be able and willing to provide written informed consent and to comply with all requirements of study participation (including all study procedures);
• Have histologically- or cytologically-confirmed diagnosis of advanced solid tumor;
• Available archived tumor tissue sample to allow for correlative biomarker studies. In the setting where archival material is unavailable or unsuitable for use, the subject must consent and undergo fresh tumor biopsy;
• Eastern Cooperative Oncology Group (ECOG) Performance Score of 0 or
• Subject must have at least one measurable lesion according to RECIST Version1.1;
• Adequate organ function;
• Females of childbearing potential and non-sterilized males who are sexually active must use an effective method;
• Adequate life expectancy.

Exclusion Criteria

• History of severe hypersensitivity reactions to other mAbs;
• Major surgical procedure within 30 days prior to the first dose of AK112 or still recovering from prior surgery;
• Receipt of any immunotherapy, any conventional or investigational systemic anticancer therapy within 4 weeks prior to the first dose of AK112 except for treatment with small-molecule tyrosine kinase-targeted agents within 2 weeks prior to the first dose of AK112;
• History of primary immunodeficiency;
• Active or prior documented inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis);
• History of organ transplant or hematopoietic stem cell that requires use of immunosuppressives;
• Known allergy or reaction to any component of the AK112 formulation;
• History of interstitial lung disease or non-infectious pneumonitis except for those induced by radiation therapies;
• Known history of tuberculosis;
• Known history of HIV;
• Receipt of live attenuated vaccination within 30 days prior to the first dose of AK112;
• Any condition that, in the opinion of the investigator, would interfere with evaluation of the investigational product or interpretation of subject safety or study results.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Akeso

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Sun Yat-sen University Cancer Center

Guangzhou, Guangdong, China

Countries

China

References

Wang F, Wei X, Zheng Y, Wang J, Ying J, Chen X, Luo S, Luo H, Yu X, Chen B, Ma L, Xu R. Safety, Pharmacokinetics, and Pharmacodynamics Evaluation of Ivonescimab, a Novel Bispecific Antibody Targeting PD-1 and VEGF, in Chinese Patients With Advanced Solid Tumors. Cancer Med. 2025 Mar;14(6):e70653. doi: 10.1002/cam4.70653.

Reference Type: DERIVED

PMID: 40114411 (View on PubMed)

Other Identifiers

AK112-102

Identifier Type: -

Identifier Source: org_study_id